1 INTRODUCTION {#SEC1}
==============

Evolutionary and functional relationships between proteins can be reliably inferred by the comparison of their sequences and benefits from a well-understood extreme value distribution (EVD) model that can be applied on a large scale (Altschul *et al.*, [@B1]; Claverie, [@B16]; Levitt and Gerstein, [@B41]; Pearson, [@B51]). When the sequence similarity is not statistically significant, remote protein relationships can often still be detected by global 3D structure comparison since protein structures are more conserved than protein sequences. Although a rigorous statistical model for global structure comparison is difficult to derive, it has been empirically shown that the structural comparison score follows an EVD if a summarized structural alignment score, rather than a root mean square deviation (RMSD), is used (Levitt and Gerstein, [@B41]). Recently increasing evidence suggests that proteins can be related by their ligand-binding sites even when global sequence or structure similarity cannot be detected (Gerlt and Babbitt, [@B23]; Scheeff and Bourne, [@B58]; Weber *et al.*, [@B73]; Xie and Bourne, [@B76]). Consequently mapping of protein space by ligand-binding site similarity will increase our understanding of divergent and convergent evolution and the origin of proteins (Gerlt and Babbitt, [@B23]; Gherardini *et al.*, [@B24]; Scheeff and Bourne, [@B58]; Xie and Bourne, [@B76]), and improve our ability to predict unknown protein functions (Binkowski *et al.*, [@B7]; Dobson *et al.*, [@B20]; Kinoshita *et al.*, [@B33]; Kinoshita and Nakamura, [@B34]; Kuhn *et al.*, [@B38]; Laskowski *et al.*, [@B40]; Pazos and Sternberg, [@B50]; Powers *et al.*, [@B53]; Schmitt *et al.*, [@B59]; Tseng *et al.*, [@B70]). Moreover, recently we have shown that such ligand--binding-site mapping can contribute to the design of pharmaceuticals through the detection of off-targets (Kinnings *et al.*, [@B32]; Xie *et al.*, [@B77]; Xie *et al.*, [@B78]).

A number of algorithms have been developed for the comparison of ligand-binding sites (Artymiuk *et al.*, [@B3]; Barker and Thornton, [@B4]; Binkowski *et al.*, [@B7]; Brakoulias and Jackson, [@B10]; Cammer *et al.*, [@B12]; Campbell *et al.*, [@B13]; Chen *et al.*, [@B14]; Green, [@B25]; Ivanisenko *et al.*, [@B29]; Jambon *et al.*, [@B30]; Kinoshita *et al.*, [@B33]; Kinoshita and Nakamura, [@B34]; Kleywegt, [@B36]; Laskowski *et al.*, [@B40]; Mardia *et al.*, [@B42]; Meng *et al.*, [@B44]; Morris *et al.*, [@B45]; Pickering *et al.*, [@B52]; Schmitt *et al.*, [@B59]; Shulman-Peleg *et al.*, [@B61]; Siggers *et al.*, [@B62]; Stark and Russell, [@B65]; Stark *et al.*, [@B65]; Torrance *et al.*, [@B69]; Wallace *et al.*, [@B72]; Zhang and Grigorov, [@B79]). Using these algorithms, the similarity between two sites is measured using geometric criteria such as RMSD (Russell, [@B57]; Stark *et al.*, [@B65]), spherical harmonic expansion (Morris *et al.*, [@B45]), residue conservation based on an amino-acid substitution matrix (Binkowski *et al.*, [@B7]; Laskowski *et al.*, [@B40]) or a Tanimoto Index (TI)-like measurement that is based on residue clusters (Stark and Russell, [@B65]; Zhang and Grigorov, [@B79]), atom types (Jambon *et al.*, [@B30]; Schmitt *et al.*, [@B59]) or surface electrostatic potentials (Kinoshita *et al.*, [@B33]). Correspondingly, five types of probabilistic models have been developed to assess the statistical significance of the ligand--binding-site match. Russell (Russell, [@B57]) and Binkowski *et al.* (Binkowski and Joachimiak, [@B8]) build a score look-up table from millions of random matches. Stark *et al.* have developed a geometrical model to estimate a priori significance of RMSD in atomic positions (Stark *et al.*, [@B65]). Davies *et al.* extend the TI-based measurement to a Poisson Index (PI) model that relies on a well-defined theoretical framework of Poisson processes (Davies *et al.*, [@B17]). It has been shown that the PI model significantly outperforms the TI model. Unlike the above two models that only use crude classifications of residues, atomic types or surface properties, Binkowski *et al.* (Binkowski *et al.*, [@B7]) and Laskowski *et al.* (Laskowski *et al.*, [@B40]) assess the significance of the similarity by quantitatively measuring the ligand--binding-site sequence alignment based on amino-acid substitution matrices. Chen *et al.* have devised a non-parametric statistical model that in theory can be applied to any scoring function (Chen *et al.*, [@B14]) but still requires a predefined template site.

We have developed a new sequence-order-independent profile--profile alignment (SOIPPA) algorithm for ligand-binding-site comparison (Xie and Bourne, [@B76]). SOIPPA has several features that distinguish it from other existing methods. Prior knowledge of both the location and the boundary of the ligand-binding site is not required. Instead, whole proteins are scanned to find the most similar local patch in the spirit of local sequence alignment such as the Smith--Waterman algorithm (Smith and Waterman, [@B64]). This feature makes SOIPPA suitable for practical problems since typically the boundary of the ligand-binding site is not clearly defined and depends on the bound ligand. In addition, two globally dissimilar ligand-binding sites may share a similar sub-site to accommodate the same molecular moiety even though the overall ligand is different and can be detected by SOIPPA. SOIPPA integrates geometric, evolutionary and physical information into a unified similarity score akin to a sequence alignment score. Stated another way, SOIPPA uses a quantitative measure of residue conservation as found in an amino-acid substitution matrix or more sensitive profile--profile score. However, unlike conventional sequence alignment, the SOIPPA alignment is sequence order independent as its name suggests; a necessary requirement when comparing local-binding sites, since the associated functional residues may not follow the same sequence order in different proteins.

The local alignment and the scoring function used by SOIPPA impose a new challenge in assessing the statistical significance of the binding-site comparison. Most of the existing statistical models cannot be applied because they only take into account the matching of a fixed number of vertices between two sites. Moreover, the matching vertex algorithms only use a crude classification of amino-acid conservation or atom physical properties rather than the quantitative measurement used by SOIPPA. Although the Binkowski--Laskowski model uses the summarized quantitative residue conservation score, it only considers the sequence order dependent case. A non-parametric statistical-based method has been proposed previously (Binkowski *et al.*, [@B7]; Chen *et al.*, [@B14]; Xie and Bourne, [@B76]; Xie *et al.*, [@B78]). However, it requires a fixed size for the template ligand-binding site. In addition, at least hundreds of additional comparisons are needed to derive the background distribution. As a result, it cannot be scaled to a genome-wide study of binding-site comparisons.

Here, we report a new statistical model that is nearly identical to the well-known EVD used in sequence and structural alignment. We find that the score of the local-site matching using SOIPPA also follows an EVD, but independent on the sequence order and the predefined ligand-binding site. Benchmark studies show that the new statistical model performs at least two-orders faster than the previous non-parametric method without sacrificing database search sensitivity and specificity. The unified statistical framework for sequence, structure and ligand-binding site comparison makes it possible to study protein relationships at multi-scales. The algorithm proposed in the article has been implemented in software SMAP v1.4, which is available from <http://funsite.sdsc.edu>.

Owing to scalability and robustness of SOIPPA and the EVD model, we have successfully applied SMAP to drug discovery, including elucidation of the molecular mechanisms of drug side-effects and repurposing of safe pharmaceuticals to target different pathways (Kinnings *et al.*, [@B32]; Xie *et al.*, [@B77]; Xie *et al.*, [@B78]). Here, we report the construction of a structural genome-wide protein interaction network of *Mycobacterium tuberculosis* using SMAP. The network provides a first step in rationally designing multi-target therapeutics to combat drug-resistance tuberculosis.

2 METHODS {#SEC2}
=========

2.1 Representation of protein structures {#SEC2.1}
----------------------------------------

We represented protein structures using Delaunay tessellation of Cα atoms that are characterized by geometric potentials (Xie and Bourne, [@B76]). The regular tessellation generates a mesh surface surrounding the Cα atoms. A normal vector that is perpendicular to the mesh surface can be assigned to each Cα atom. The regular tessellation of the protein structure also encodes a graph representation in 3D space. The nodes of the graph are the Cα atoms. The connections in the regular tessellation form the edges. We used the graph representation of the structure in the ligand-binding site comparison described below.

### 2.1.1 Local protein sequence order independent alignment {#SEC2.1.1}

We aligned two proteins using the sequence order independent profile--profile alignment (SOIPPA) algorithm (Xie and Bourne, [@B76]). The algorithm is based on finding the [m]{.ul}aximum- [w]{.ul}eight [c]{.ul}ommon [s]{.ul}ub-graph (MWCS) between two encoded protein graphs. A weight is assigned according to the chemical similarity or evolutionary correlation of the associated sites. In this article, the McLachlan chemical similarity matrix (McLachlan, [@B43]) and BLOSUM45 substitution matrix (Henikoff and Henikoff, [@B28]) were used for chemical similarity and for evolutionary correlation, respectively. The MWCS is implemented with a branch-bound algorithm (Kumlander, [@B39]; Ostergard, [@B47]; Ostergard, [@B48]).

2.2 Scoring function for ligand-binding site similarity {#SEC2.2}
-------------------------------------------------------

After two structures are superimposed according to the alignment, the binding-site similarity is measured using a Gaussian density function *S*~*ij*~ as follows:

where *M*~*ij*~ is the residue similarity determined by the substitution matrix between two residues of proteins *i* and *j*, respectively. Here the McLachlan physical similarity matrix (McLachlan, [@B43]) and BLOSUM45 substitution matrix were used (Henikoff and Henikoff, [@B28]). *pa*~*ij*~ and *pd*~*ij*~ are determined as follows: where α~*ij*~ and *d*~*ij*~ is the angle and the distance between the two Cα atoms, respectively. The angle is calculated from the inverse cosine of the dot product between the normal vectors of the two Cα atoms. The parameters used in the calculation are empirical and not optimized.

2.3 Statistical model {#SEC2.3}
---------------------

To derive a background distribution of raw scores for binding-site similarity, 36 structures with different CATH architectures were randomly selected from the RCSB Protein Data Bank (PDB) (Berman *et al.*, [@B6]; Deshpande *et al.*, [@B19]). These chains are shown in [Table 1](#T1){ref-type="table"}. Table 1.PDB chains used for deriving the background distribution for SOIPPA score statisticsPDB IDChain IDCATH ID1YOZA1.10.32001YO7A1.20.14401B3UA1.25.101PPRA1.40.101AGMA1.50.101MVFC2.10.2601C3KA2.100.101N7VA2.105.10, 2.60.330, 2.70.2501GENA2.110.101GYDA2.115.101A14A2.120.101A0RA2.130.101AOMA2.140.101P9HA2.150.101EWWA2.160.101T2RB2.170.2601MKNA2.20.601YDUA2.30.2401XKCA2.40.3201KSAA2.50.101ABRB2.80.101B2PA2.90.101VKBA3.10.4901BP1A3.15.101YBEA3.20.1402SICC3.30.3501Y0KA3.40.15401J7GA3.50.801J5UA3.55.102PVAA3.60.601A2NA3.65.101AXCA3.70.101BWDA3.75.101A4YA3.80.101YB5A3.90.1804MT2A4.10.10

The residues from the above structures were randomly shuffled 100 times to construct a total of 3600 structural models. Two structural models whose templates belong to different CATH classes were aligned using the SOIPPA algorithm. In the end, a total of 8 46 711 alignments were generated and used in the model fitting. The alignment length ranges from 3 to 63. As shown in [Figure 1](#F1){ref-type="fig"}, the alignment scores for given alignment lengths fit EVD: where: where *S* is the raw SOIPPA similarity score. As shown in [Figure 2](#F2){ref-type="fig"}, μ and σ are fitted to the logarithm of *N*, which is the alignment length between two proteins: Six parameters *a*, *b*, *c*, *d*, *e* and *f* are derived from the linear regression of the above formula using *R* (<http://www.r-project.org>), resulting in *a* = 17.242, *b* = −40.911, *c* = 46.138, *d* = 5.998, *e* = −12.370 and *f* = 25.441 for the BLOSUM45 matrix and *a* = 5.963, *b* = −15.523, *c* = 21.690, *d* = 3.122, *e* = −9.449 and *f* = 18.252 for the McLachlan similarity matrix, respectively. Fig. 1.Fitting of the square of the SOIPPA raw scores to an extreme value distribution (EVD) for alignment lengths *N* of 5, 15, 25 and 35, respectively. The EVD is determined by two parameters μ and σ, which are estimated from linear regression of the rearrangement of Equations [4](#M4){ref-type="disp-formula"} and [5](#M5){ref-type="disp-formula"} (see text and [Fig. 2](#F2){ref-type="fig"}) as *S*^2^ = μ + σ(--ln(--ln(1−-*P*))). Fig. 2.The derived parameters μ and σ that determine a unique extreme value distribution (EVD) for a specific alignment length can be fitted to a quadratic function based on the logarithm of alignment length.

2.4 Benchmark data {#SEC2.4}
------------------

The benchmark data used in this article is the same as that from a previous study (Xie and Bourne, [@B76]). In brief, a set of 247 protein monomer chains, which are bound to the following ligands, ATP, ADP, NAD, FAD, SAM and SAH, were selected as positive controls from the RCSB PDB (Berman *et al.*, [@B6]; Deshpande *et al.*, [@B19]). One hundred and one protein complex structures not bound to a ligand-containing ribose, adenine, flavin and nicotinamide were extracted from the PDB as negative controls. The sequence identity between each pair of chains was below 30%.

2.5 Performance evaluation {#SEC2.5}
--------------------------

We evaluated sensitivity and specificity of the ligand-binding site search using a true and false positive rate as defined in the previous article (Xie and Bourne, [@B76]): Time complexity of the algorithm was evaluated by querying 5000 non-redundant PDB chains to two randomly selected structures (PDB id: 1AU1 and 1ZY9). Their chain lengths are 166 and 564, respectively. The computation was executed on a personal computer with an Intel Xeon 3.00 GHz CPU.

2.6 Construction of the protein--ligand interaction network of *M. tuberculosis* {#SEC2.6}
--------------------------------------------------------------------------------

We first download the genome of *M. tuberculosis* H37Rv strain from the TB Database ([www.tbdb.org](www.tbdb.org)). All available non-redundant *M. tuberculosis* structures were extracted from the PDB. These structures cover 232 out of 3999 open reading frames in the whole *M. tuberculosis* genome. We compared the biological units of the 232 structures with each other using SMAP; a total of 232 × (232 -- 1)/2 = 26 796 pairs were generated. A predicted *M. tuberculosis* protein--ligand interaction network is constructed. In the network, the node is one of the 232 structures. An edge is formed if SMAP *P*-value is less than 1.0E--7 for the pair-wise alignment between two structures. The nodes are ranked based on their connectivity to others from high to low.

2.7 Determination of the druggability of the predicted *M. tuberculosis* targets {#SEC2.7}
--------------------------------------------------------------------------------

The druggability of the top 18-ranked proteins was assessed by using them as queries to scan a set of 305 protein--drug complex structures. The drug-binding structures were extracted from SuperTarget (Gunther *et al.*, [@B27]). The binding site in the *M. tuberculosis* target was predicted from the alignment between the target and the drug-binding site. Finally, the drug was docked to the predicted drug-binding site using the protein--ligand docking software eHiTs (Zsoldos *et al.*, [@B80]).

3 RESULTS {#SEC3}
=========

3.1 EVD for the SOIPPA alignment score {#SEC3.1}
--------------------------------------

We have improved both the speed and accuracy of our original ligand-binding site similarity search algorithm (Xie and Bourne, [@B76]) using the new statistical model. Previously the statistical significance of the ligand-binding site similarity was estimated based on a non-parametric statistical method (Xie and Bourne, [@B76]). It required hundreds of additional comparisons for each binding site to establish a background distribution. Here, we report a unified statistical framework similar to that used in sequence and structure comparison (Levitt and Gerstein, [@B41]) where the significance of binding-site similarity can be estimated at least two orders of magnitude faster than for the original non-parametric method.

We find that the probability density distribution of the square of the raw binding-site similarity score fits EVD that is only dependent on the alignment length, as shown in [Figure 1](#F1){ref-type="fig"}. The EVD is uniquely determined by two parameters μ and σ (see 'Methods' section), which can be fitted to the logarithm of the number of aligned residues ([Fig. 2](#F2){ref-type="fig"}). Thus the *P*-value of the observed similarity can be computed analytically from the given distribution for any pair of ligand-binding sites with any number of residues.

### 3.1.1 Performance of the EVD model {#SEC3.1.1}

The new EVD model improves the database search speed of SOIPPA by at least two-order of magnitude when compared to the non-parametric method that requires hundreds of comparisons to derive a background distribution (Xie and Bourne, [@B76]; Xie *et al.*, [@B78]). Using the EVD model, the majority of computation is spent in the MWCS optimum alignment step. As shown in [Figure 3](#F3){ref-type="fig"}, the total computational time for each comparison is approximately linearly dependent on the number of residues in the structure, although the underlying MWCS algorithm itself is NP hard. Because we use the geometric potential to reduce the search space, the computational time also depends on the surface properties of the structure. A structure with a smooth surface will be much faster than a structure with a rough surface. It takes ∼60 s to compare two polypeptide chains each of 500 residues. Fig. 3.Computational time for 5000 randomly selected non-redundant chains searched against two structures with chain lengths of 564 (red triangle) and 166 (black diamond), respectively.

Moreover, the sensitivity and specificity of the database search is not sacrificed but slightly improved when compared with the non-parametric statistical method (Xie and Bourne, [@B76]). As shown in [Figure 4](#F4){ref-type="fig"}, the true positive rate increases around 2% and 1% for BLOSUM45 and McLachlan substitution matrix, respectively, when the false positive rate is 1%. The benchmark that is used for the evaluation is given in the method section. As shown previously (Xie and Bourne, [@B76]), a weighted scoring scheme as used by SOIPPA outperforms a non-weighted vertex matching method as used by most-existing algorithms. Thus, SOIPPA using the EVD statistical model represents progress toward establishing a robust, accurate and scalable ligand-binding-site-comparison methodology. Fig. 4.Percentage of false positive rate versus true positive rate for the original SOIPPA algorithm (Xie and Bourne, [@B76]) (solid) and the improved SMAP implementation (dashed with circles) using (**a**) BLOSUM45 and (**b**) McLachlan substitution matrices. The details of the benchmark used are given in the method section.

### 3.1.2 Application to drug discovery {#SEC3.1.2}

Given the improved speed and accuracy of SOIPPA, the new statistical model permits us to search for ligand--binding-site similarity on a genome-wide scale. We have implemented both the SOIPPA and the EVD model into software called SMAP. Using SMAP, we have successfully identified off-targets for several pharmaceuticals either already on the market or in clinical trials. In one case we have revealed a complex off-target-binding network for cholesteryl ester transporter protein (CETP) inhibitors (Xie *et al.*, [@B77]). The identified off-targets are involved in both positive and negative control of blood pressure, providing a molecular basis for the underlying clinical indications of CETP inhibitors.

Here, we further apply SMAP to an all-against-all ligand--binding-site comparison across the *M. tuberculosis* structural genome in an effort to construct a genome-scale protein--ligand interaction network. Our purpose is to discover protein clusters that have similar ligand--binding sites and hence are good drug target candidates to rationally design promiscuous drugs that are able to inhibit multiple targets. It is believed that multi-target therapy is more effective than single-target therapy to treat parasitic diseases such as drug-resistant tuberculosis (Kitano, [@B35]). In addition, such protein--ligand interaction networks may provide molecular insights into the mechanism of drug resistance (Raman and Chandra, [@B54]). In our initial study of 232 non-redundant *M. tuberculosis* proteins, SMAP generates a highly connected network with highly a confident *P*-value cut-off of 1.0e--7. As shown in [Figure 5](#F5){ref-type="fig"}, 144 proteins form a large single linkage cluster. The top 18 mostly highly connected proteins are listed in [Table 2](#T2){ref-type="table"}. The list is dominated by dehydrogenases and reductases, including the most-studied *M. tuberculosis* drug target Enoyl-\[acyl-carrier-protein\] reductase (InhA). The drug isoniazid that targets InhA has been the most used first-line anti-tuberculosis therapy for decades. The gene Rv3303c that encodes the most connected dihydrolipoamide dehydrogenase (LPDA) in the network is found to be up-regulated during infection and growth *in vivo* (Deb *et al.*, [@B18]). Besides dehydrogenases and reductases, other highly connected proteins such as inorganic polyphosphate/ATP--NAD kinase and serine protease PEPD play key roles in bacterial survival but to date orthologs have not been found in higher-order eukaryotes (Brown and Kornberg, [@B11]; Ribeiro-Guimarães and Pessolani, [@B56]). Recently, inhibitors of inorganic polyphosphate/ATP--NAD kinase have been developed (Bonnac *et al.*, [@B9]). Thus, most of the proteins listed in [Table 2](#T2){ref-type="table"} are potential novel drug targets for the development of efficient anti-tuberculosis chemotherapeutics. Fig. 5.Predicted protein--ligand interaction network of *M. tuberculosis*. Proteins that are predicted to have similar binding sites are connected. Squares represent the top 18 most connected proteins. Table 2.Top 18 mostly connected proteins (number of neighbors \> 12) in the protein--ligand interaction network of *M.tuberculosis*PDB idProtein nameGene nameLinksSMAP *P*-value[^a^](#TF1){ref-type="table-fn"}Drug PDB id[^b^](#TF2){ref-type="table-fn"}eHits Score1xdiDihydrolipoamide Dehydrogenase LPDARv3303c240.000NMG−5.562iedEnoyl-\[acyl-carrier-protein\] reductase \[NADH\]Rv148420Drug target of isoniazid1u0rInorganic polyphosphate/ATP-NAD kinaseRv1695209.904E-6FNM−4.591me5Alkyl hydroperoxide reductase ahpDRv2429207.187E-4P1Z−4.232i3gN-acetyl-gamma-glutamyl-phosphate reductaseRv1652171.810E-72ML−3.981tedChalcone/stilbene synthase family proteinRv1372175.119E-6OHA−5.123ddnD-3-phosphoglycerate dehydrogenaseRv2996c168.245E-6ROC−8.003cy1Cytochrome P450 121Rv227616Drug metabolizing enzyme1y8tSerine Protease PEPDRv0983169.565E-4505−3.962vp8Dihydropteroate Synthase 2Rv1207159.458E-4E3O−4.662q74Inositol-1-monophosphataseRv2701c158.944E-5ID2−2.572c7gNADPH-ferredoxin reductase fprARv3106149.992E-16URF−4.342c45Aspartate 1-Decarboxylase PrecursorRv3601c141.259E-3RIS−0.381nfr3-α-(or 20-β)-hydroxysteroid dehydrogenaseRv2002141.000E-9TOY−5.152qj3Malonyl CoA-acyl carrier protein transacylaseRv2243122.507E-5E3O−4.382a87Thioredoxin reductaseRv3913124.957E-11RBF−6.071yl7Dihydrodipicolinate reductaseRv2773c123.918E-5BA3−3.781v92NSFL1 cofactor p47Rv2150c12\>1.000E-2----[^1][^2]

To further assess the druggability of the enzymes that are listed in [Table 2](#T2){ref-type="table"}, but have not been actively pursued by the pharmaceutical industry, using SMAP we compared and superimposed them with complex structures that bind to existing drugs in PDB. The superimposition generates a predicted binding pose of the drug with the target. The surrounding residues of the drug can be considered as the predicted drug-binding site. Furthermore, we docked the drug molecules to the predicted drug-binding site using the software eHiTs (Zsoldos *et al.*, [@B80]). The estimated binding affinity indicated whether or not the predicted binding site is favorable for drug binding. In addition, it provided valuable clues for repurposing safe pharmaceuticals to treat tuberculosis (Kinnings *et al.*, [@B32]). As shown in [Table 2](#T2){ref-type="table"}, most of the predicted binding sites were similar to a known drug-binding site with high statistical significance (*P*-value \< 1.0E--4). Moreover, the docking scores suggested that the drug-like molecule could fit into most binding sites.

4 DISCUSSION {#SEC4}
============

Unlike similar sequences or structures, sequence order is not always conserved between two similar functional sites. This presents a problem in achieving the optimum alignment of two ligand-binding sites. Further, most current alignment algorithms only use a crude classification of amino-acid conservation rather than a quantitative measurement such as those presented in an amino-acid substitution matrix. Exceptions can be found (Binkowski *et al.*, [@B7]; Laskowski *et al.*, [@B40]; Pazos and Sternberg, [@B50]; Powers *et al.*, [@B53]) but sequence order constraints are usually imposed. To address the issues of sequence order independence and evolutionary conservation, we encode amino-acid residues in the ligand-binding site as an undirected graph. Using the graph representation, two ligand-binding sites can be aligned by finding the MWCS. Although the maximum-size clique algorithm without weights has been widely used in chemo and bioinformatics, incorporation of the weights into the comparison makes fundamental differences. Analogous to conventional sequence alignment without weights, the similarity between two aligned sequences can only be measured with sequence identity. With weights such as a value from a substitution matrix incorporated into the sequence comparison, similarity scores can capture more evolutionary and physio-chemical information and give more statistically meaningful results. As demonstrated previously, the MWCS-based SOIPPA algorithm outperform the non-weighted method (Xie and Bourne, [@B76]). However, the SOIPPA algorithm imposes new challenges on the efficient assessment of statistical significance because the conventional probability model that is developed based on vertex matching cannot be applied. Previously, a background distribution has been derived from hundreds of random alignments. Then the *P*-value is estimated using a non-parametric statistical method. In this article, we have found that the weighted score from the MWCS alignment follows EVD nearly identical to global sequence and structure alignment. It allows us to develop an efficient unified statistical framework to compare two proteins at multiple scales. The EVD model eliminates the requirement for additional alignments that are used to generate the background distribution, and thus speeds up the computation for a pair-wise comparison of ligand-binding sites by at least 100-fold. As a result, it is possible for us to apply ligand-binding site similarity searching to complete genomes. It took less than 1 week to compute an all-against-all comparison of the *M. tuberculosis* structural genome on a PC with one 3.0 GHz CPU.

The algorithm presented in this article can be further improved in the future. The Mclachlan (McLachlan, [@B43]) and BLOSUM45 (Henikoff and Henikoff, [@B28]) amino-acid substitution matrixes used in this study are derived from whole proteins or domains and hence are not customized for the ligand-binding site. By using a scoring matrix that is specific to an individual binding site, the performance of inferring protein functions can be dramatically improved (Tseng *et al.*, [@B70]; Tseng and Liang, [@B71]). It will be interesting to apply the EVD model developed here using a ligand-binding-site-specific scoring matrix. Moreover, it is a challenge to randomly sample ligand-binding site space by taking into account both protein surface geometry and amino-acid composition. The common practice is to use a non-redundant set of thousands of PDB structures to build a look-up table (Binkowski and Joachimiak, [@B8]). However, the structural coverage in PDB is highly biased (Xie and Bourne, [@B75]). This bias is especially true for ligand-binding sites. The PDB is dominated by ligands such as nucleotides and their analogs. More fundamental, growing evidence indicates that protein space could be continuous and related by ligand-binding sites (Andreeva and Murzin, [@B2]; Bashton and Chothia, [@B5]; Choi and Kim, [@B15]; Fong *et al.*, [@B21]; Friedberg and Godzik, [@B22]; Grishin, [@B26]; Kolodny *et al.*, [@B37]; Pan and Bardwell, [@B49]; Reeves *et al.*, [@B55]; Shindyalov and Bourne, [@B60]; Taylor, [@B68]; Winstanley *et al.*, [@B74]; Xie and Bourne, [@B76]). Thus, it may not be appropriate to derive the background distribution directly from existing structures as they are not structurally, functionally and evolutionarily random. Keeping this in mind, we selected a set of structures from different CATH classes and built random models seeded from them. These models are the least likely to be directly related. However, one may argue that the number of models that are used to generate the background distribution is still small. Although the sequence space can be sufficiently sampled by varying the sequence composition and order, the random geometric sampling is limited by total number of residues in the 36 structures, which is in the order of 10^7^. To improve the random sampling of the protein surface, decoy structures could be used as in structural comparison (Taylor, [@B67]). We are in the process of developing the random decoy structure model and deriving a more robust and reliable statistical model for the ligand-binding site search. Finally, the geometric statistical model may also be affected by how we represent the protein structure. Because we only use a Cα representation in SOIPPA for the purpose of applying it to homology models, it is not clear if the EVD estimation is applicable to the ligand-binding site comparison when using an all-atom presentation.

Our initial study of the *M. tuberculosis* protein--ligand interaction network indicates that it is possible to design promiscuous drugs that are able to inhibit multiple proteins within the organism because a number of proteins share the similar ligand-binding sites with each other. The predicted binding network may also establish new opportunities to combat drug resistance. There are three types of known drug resistance mechanisms: (i) mutations in the drug targets and the regulatory genes through SOS response such as cytochrome P450 (Johnson *et al.*, [@B31]), (ii) activation of efflux pumps and drug modifying enzymes (Nguyen and Thompson, [@B46]) and (iii) acquisition of drug detoxification genes through horizontal gene transfer (Smith and Romesberg, [@B63]). Recently, Raman *et al.* have constructed and analyzed a TB protein--protein interaction network and identified several resistance pathways involving the above mechanisms (Raman and Chandra, [@B54]). There is no doubt that a detailed ligand-binding site analysis between the drug target and the genes that are responsible for drug resistance will provide invaluable clues in designing drugs that inhibit not only essential genes but also co-targets that are not necessarily essential for the bacteria to survive but mediate drug resistance. Even in our initial small-scale study, we identify one of such protein, cytochrome P450 121 that has shown significant binding-site promiscuity with a number of potential drug targets (rank 8 in [Table 2](#T2){ref-type="table"}). To develop antibacterial therapies that are less liable to drug resistance, the inhibitor should be designed to retain binding to the primary targets but reduce binding to co-targets such as cytochrome P450. Another strategy is to develop combined therapeutics that inhibits the target and the co-target simultaneously. More studies are required to validate our findings. We need to understand how proteins are involved in metabolic, gene regulation and signal transduction pathways; what roles they play in drug resistance and whether or not they have cross-reactivity with human proteins. A chemical systems biology approach, which integrates the protein--ligand interaction network outlined in the article along with the reconstruction and the simulation of the biological pathways, will play a critical future role in addressing these issues. Our own efforts in this direction are on going.
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[^1]: ^a^Presents the lowest *P*-value between the identified hub proteins and 305 proteins binding with existing drugs in PDB.

[^2]: ^b^Presents the drugs with the lowest eHiTs score when docked to the identified hub proteins.
